Nerium Biotechnology Reports Restated Financial Results

(firmenpresse) - SAN ANTONIO, TEXAS -- (Marketwired) -- 12/01/14 -- Nerium Biotechnology, Inc. (the "Company"), announced today that, due to a mathematical formula error in its equity investment calculations, it has restated its consolidated balance sheets as at September 30, 2013; December 31, 2013; March 31, 2014 and June 30, 2014 and its consolidated statements of income and comprehensive income for the three-month and nine-month periods ended September 30, 2013; the year ended December 31, 2013; the three-month period ended March 31, 2014; and the three-month and six-month periods ended June 30, 2014. There was no significant impact on the cash flows of the Company as these adjustments represent non-cash items.

Restatement of Documents

The Company intends to include the effect of this restatement, where applicable, in its interim condensed consolidated financial statements for September 30, 2014 to be filed with the Canadian securities regulators and available for review at . The SEDAR filing also will include a related management's discussion and analysis.

Impact of the Restatement

The following tables summarize the corrections on each of the affected consolidated financial statement line items presented in the respective financial statements:





About Nerium Biotechnology, Inc.

Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company's shares are not listed on any stock exchange or quotation system.



Contacts:
Nerium Biotechnology, Inc.
Joseph B. Nester
CFO

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 01.12.2014 - 23:48 Uhr
Sprache: Deutsch
News-ID 356372
Anzahl Zeichen: 0

contact information:
Town:

SAN ANTONIO, TEXAS

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 184 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Nerium Biotechnology Reports Restated Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von

Nerium Biotechnology, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Nerium Biotechnology Shareholders Overwhelmingly Elect All Six Management Nomine ...

SAN ANTONIO, TEXAS -- (Marketwired) -- 06/30/17 -- Nerium Biotechnology, Inc. ("Nerium" or the "Company") is pleased to announce the voting results of its annual meeting of shareholders (the "Meeting") held on June 29, ...

Nerium Biotechnology Issues Shareholder Letter and Commences Selling NeriumAD Ad ...

SAN ANTONIO, TEXAS -- (Marketwired) -- 06/15/17 -- Nerium Biotechnology, Inc. ("Nerium" or the "Company") today announces that it is mailing a letter to shareholders in advance of the Company's annual meeting on June 29, 20 ...

Nerium Biotechnology to Sell NeriumAD to Nerium International, LLC for Distribut ...

SAN ANTONIO, TEXAS -- (Marketwired) -- 11/21/16 -- Nerium Biotechnology, Inc. ("Nerium" or the "Company") reported today that its subsidiary, Nerium SkinCare, Inc. ("Nerium SkinCare") has agreed to provide its propriet ...

Alle Meldungen von Nerium Biotechnology, Inc.